Department of Health & Ageing You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your tenure? Prime Minister Gillard announced during the last election in 2010 that both mental health reform and aged care reform…
Boehringer Ingelheim Benelux Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period of strong growth for the company based on the portfolio which we had. Today, however, following a strong focus on…
AstraZeneca Australia You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at the overall market, the biggest changes have been the various reforms to the Pharmaceutical Benefits Scheme (PBS). PBS reform started…
Pfizer Pfizer completed the acquisition of Wyeth three years ago. How did the merge impact the Singaporean operations? As the result of the merge, Pfizer in Singapore has been able to provide a much more comprehensive portfolio and meet more patient needs in the country. It also opened new therapeutic areas…
Albany Molecular Research Prior to joining AMRI you worked in diverse companies in Japan, like Dishman, Pfizer and Bayer. What attracted you to this company? The main reason is that Singapore has growing opportunities in drug discovery. I worked for a few years in business development with Dishman and although I enjoyed this…
Novo Nordisk - Belgium Looking into your background, we see that you have developed your career in the local industry’s top 3 players: Pfizer, AstraZeneca and Novartis until assuming your position as General Manager of Novo Nordisk BeLux less than a year ago. What motivated you to join the company back in 2010 and…
Oystershell Oystershell was founded in 1979, however in 2002 the company was taken over by you and your team in a MBO. Can you tell our readers more about what motivated this decision and how you have transformed the company in the 10 years since? Over time, it had become clear…
B & C Group Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career, it became apparent to me that that the supply chain was highly fragmented. In 1999, I decided to found B&C…
A* Star Singapore’s proclaimed key strengths are: an educated and skilled workforce, a supportive government, great business and regulatory environment, and government-supported research institutes. What role has A* STAR played in building these capabilities? A decade ago the biomedical industry in Singapore was relatively modest and there was little research activities outside…
Australian Self Medication Industry (ASMI) As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine, what made you decide to join ASMI as a Scientific Director in 2004 and Executive Director in July 2010? My…
Generic Medicines Industry Association (GMiA) In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We have been focusing on several strategic priorities over the past four years, firstly on creating a viable commercial environment for…
Biogen Idec Czech Republic Ms. Hrdličková, can you please begin by introducing yourself to our readers, and providing a brief overview of your pharmaceutical career? My educational background is in general and molecular biology, with a specialization in microbiology. I worked for approximately three years doing clinical work in this field at a hospital,…
See our Cookie Privacy Policy Here
